EP102: METTL3 Inhibitor Compound Data for Solid Tumors and AML

A dataset discloses lead optimization results for a series of METTL3 inhibitors, culminating in the discovery of compound EP102. The data, published by Guillaume Dutheuil on figshare in April 2026, includes information on structural modifications that improved oral bioavailability and decreased lipophilicity. EP102 has demonstrated efficacy in mouse tumor models and has entered clinical development for advanced solid tumors.

Use Cases

• Analyze structure-activity relationships based on described core and hinge moiety replacements.
• Model pharmacokinetic properties based on the described improvements in oral bioavailability and lipophilicity.
• Prioritize compound candidates for oncology based on the described selectivity and ADME/PK profiles.
• Benchmark preclinical efficacy based on the described results in AML and solid tumor mouse models.

Strengths

• Dataset is openly licensed under CC-BY-NC-4.0.
• File size is 1.8 KB, indicating a compact and likely focused dataset.
• Data describes a specific clinical-stage compound, EP102, with a clear development path.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from drug discovery research.

Time Range

null

Freshness

Last updated 2026-04-14 06:45:14; freshness should be verified.

Geography

null